CO5150234A1 - Agonistas de 5-ht[sub 1f] serotonina - Google Patents

Agonistas de 5-ht[sub 1f] serotonina

Info

Publication number
CO5150234A1
CO5150234A1 CO00013084A CO00013084A CO5150234A1 CO 5150234 A1 CO5150234 A1 CO 5150234A1 CO 00013084 A CO00013084 A CO 00013084A CO 00013084 A CO00013084 A CO 00013084A CO 5150234 A1 CO5150234 A1 CO 5150234A1
Authority
CO
Colombia
Prior art keywords
nr3r4
hydrogen
serotonine
agonists
sub
Prior art date
Application number
CO00013084A
Other languages
English (en)
Inventor
Filla Sandra Ann
Brian Michael Mathes
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5150234A1 publication Critical patent/CO5150234A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de fórmula I<EMI FILE="00013084_1" ID="1" IMF=JPEG >Y las sales de adición farmacéuticas del mismo, en la que;<EMI FILE="00013084_2" ID="2" IMF=JPEG >R es (a)E-D es C=CH o CH-CH 2;R1 es hidrógeno o alquilo C1-C4;R2 es hidrógeno, halo, hidroxi, -NR3R4, -SR3, -C(O)R3, -C(O)NR3R4, -NR3SO2R5, -NHC(Q)NR3R4, -NHC(O)OR3 o NR3C(O)R5;R3, R4, y R5 son, de forma independiente, hidrógeno, alquilo C1-C4, alquenilo C2-C6, alquinilo C2-C6 o -(CH2)n arilo; o R3 y R4 combinados, junto con el nitrógeno al que están unidos, forman un anillo de pirrolidina, piperidina, piperazina, piperazina sustituida en posición 4, morfolina o tiomorfolina;N es 0, 1, 2, 3, 4, 5 ó 6; yQ es O u S.
CO00013084A 1999-02-26 2000-02-24 Agonistas de 5-ht[sub 1f] serotonina CO5150234A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12201699P 1999-02-26 1999-02-26

Publications (1)

Publication Number Publication Date
CO5150234A1 true CO5150234A1 (es) 2002-04-29

Family

ID=22400069

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00013084A CO5150234A1 (es) 1999-02-26 2000-02-24 Agonistas de 5-ht[sub 1f] serotonina

Country Status (21)

Country Link
EP (1) EP1155020B1 (es)
JP (1) JP2002537398A (es)
KR (1) KR20010102355A (es)
AR (1) AR026856A1 (es)
AT (1) ATE258935T1 (es)
AU (1) AU3354000A (es)
BR (1) BR0008479A (es)
CA (1) CA2371784A1 (es)
CO (1) CO5150234A1 (es)
DE (1) DE60008073T2 (es)
EA (1) EA200100918A1 (es)
ES (1) ES2214256T3 (es)
HU (1) HUP0200245A2 (es)
ID (1) ID30056A (es)
IL (1) IL144355A0 (es)
NO (1) NO20014127L (es)
PE (1) PE20001432A1 (es)
PL (1) PL350864A1 (es)
TR (1) TR200102436T2 (es)
WO (1) WO2000050426A2 (es)
ZA (1) ZA200106109B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2004094380A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
ATE370116T1 (de) 2003-12-17 2007-09-15 Lilly Co Eli Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten
CA2795062A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
TWI829107B (zh) 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine

Also Published As

Publication number Publication date
WO2000050426A3 (en) 2000-12-21
NO20014127D0 (no) 2001-08-24
PE20001432A1 (es) 2000-12-18
DE60008073T2 (de) 2004-08-05
ID30056A (id) 2001-11-01
DE60008073D1 (de) 2004-03-11
AU3354000A (en) 2000-09-14
HUP0200245A2 (en) 2002-06-29
TR200102436T2 (tr) 2002-06-21
ATE258935T1 (de) 2004-02-15
ZA200106109B (en) 2002-07-25
BR0008479A (pt) 2002-01-29
EA200100918A1 (ru) 2002-02-28
EP1155020B1 (en) 2004-02-04
JP2002537398A (ja) 2002-11-05
NO20014127L (no) 2001-08-24
IL144355A0 (en) 2002-05-23
PL350864A1 (en) 2003-02-10
CA2371784A1 (en) 2000-08-31
KR20010102355A (ko) 2001-11-15
AR026856A1 (es) 2003-03-05
EP1155020A2 (en) 2001-11-21
WO2000050426A2 (en) 2000-08-31
ES2214256T3 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
CY1108025T1 (el) Παραγωγα n-[φαινυλο (πιπεριδινο-2-υλο)μεθυλο] βενζαμιδιου, η διαδικασια παρασκευης τους και η εφαρμογη τους στη θεραπευτικη
ES2193990T3 (es) Derivados de purina.
ATE315022T1 (de) Prostaglandinanaloga als ep4-rezeptoragonisten
ES2123829T3 (es) Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas.
PE20030440A1 (es) Fenilsulfonamidas como antagonistas de ccr3
AU2003217936A1 (en) Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
PE20040907A1 (es) Derivados de anilinopirazol
CO5150234A1 (es) Agonistas de 5-ht[sub 1f] serotonina
AU3415599A (en) Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor agents
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
MY116454A (en) Ring-substituted 2-amino-1, 2,3,4-tetra- hydronaphthalenes and 3-aminochromanes.
ES2065478T3 (es) 2-amino-1,2,3,4-tetrahidronaftalenos y 3-aminocromanos sustituidos en el anillo.
CO5150179A1 (es) Derivados de n-etilpirimidin o (piridin)-2-(1,2-benzoisoxa- zol-3-il)-octahidro-2h-pirido[1,2-a]pirazina y sus composiciones farmaceuticas
ATE289307T1 (de) 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten
FI892344A0 (fi) 6-fenyl-3-piperazinylalkyl-1h,3h -pyrimidin-2-4-dionderivat, deras framstaellning och deras terapeutiska anvaendning.
DK327286A (da) Indolcarboxamidderivater og salte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter til deres fremstilling
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
CO4650039A1 (es) Benzotiofenos amorfos, procedimientos de preparacion y procedimientos de uso
DK391182A (da) Heterocycliske forbindelser, deres fremstilling og anvendelse
YU52498A (sh) UPOTREBA 2-ARILBENZO (b) TIOFENA ZA DOBIJANJE LEKA
ES2120122T3 (es) Compuestos de vitamina d y metodo de preparar estos compuestos.
DK653788A (da) 1,4-disubstituerede piperidinyl-forbindelser samt anvendelsen heraf
WO2004110379A3 (en) A1 adenosine receptor antagonists
ES2128572T3 (es) Utilizacion de los derivados de cefem como agentes antimetastaticos.
ES462746A1 (es) Procedimiento para la preparacion de nuevas piridobenzodia- zepinas.